Contrast Agent Mass Spectrometry Imaging Reveals Tumor Heterogeneity

详细信息    查看全文

• 作者：Alessandra Tata ; Jinzi Zheng ; Howard J. Ginsberg ; David A. Jaffray ; Demian R. Ifa ; Arash Zarrine-Afsar
• 刊名：Analytical Chemistry
• 出版年：2015
• 出版时间：August 4, 2015
• 年：2015
• 卷：87
• 期：15
• 页码：7683-7689
• 全文大小：585K
• ISSN：1520-6882

文摘

Mapping intratumoral heterogeneity such as vasculature and margins is important during intraoperative applications. Desorption electrospray ionization mass spectrometry (DESI-MS) has demonstrated potential for intraoperative tumor imaging using validated MS profiles. The clinical translation of DESI-MS into a universal label-free imaging technique thus requires access to MS profiles characteristic to tumors and healthy tissues. Here, we developed contrast agent mass spectrometry imaging (CA-MSI) that utilizes a magnetic resonance imaging (MRI) contrast agent targeted to disease sites, as a label, to reveal tumor heterogeneity in the absence of known MS profiles. Human breast cancer tumors grown in mice were subjected to CA-MSI using Gadoteridol revealing tumor margins and vasculature from the localization of [Gadoteridol+K]⁺ and [Gadoteridol+Na]⁺ adducts, respectively. The localization of the [Gadoteridol+K]⁺ adduct as revealed through DESI-MS complements the in vivo MRI results. DESI-MS imaging is therefore possible for tumors for which no characteristic MS profiles are established. Further DESI-MS imaging of the flux of the contrast agent through mouse kidneys was performed indicating secretion of the intact label.